Hsa-miR-221-3p promotes proliferation and migration in HER2-positive breast cancer cells by targeting LASS2 and MBD2

• Xiying Shao ^[1] ; Yabing Zheng ^[1] ; Yuan Huang ^[1] ; Guangliang Li ^[1] ; Weibin Zou ^[1] ; Lei Shi ^[1]
  1. [1] University of Chinese Academy of Sciences

     University of Chinese Academy of Sciences

     China

     
• Localización: Histology and histopathology: cellular and molecular biology, ISSN-e 1699-5848, ISSN 0213-3911, Vol. 37, Nº. 11, 2022, págs. 1099-1112
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Background. Human epidermal growth factor receptor (HER2)-positive breast cancers account for nearly 20% of all breast cancer cases and microRNAs (miRNAs) play crucial roles in disease progression. The study was aimed to explore the role of miR-221-3p in HER2-positive breast cancer.

    Methods. Differentially expressed miRNAs were identified by high-throughput sequencing. Quantitative real-time PCR was used to evaluate mRNA levels of corresponding genes. CKK8 and transwell assays were performed to evaluate cell viability and migration. The translation binding was assessed by luciferase assay.

    Results. Hsa-miR-221-3p was highly upregulated in HER2-positive breast cancer samples, particularly in patients with advanced or metastatic disease, as compared to healthy controls. miR-221-3p upregulation using mimics promoted cell proliferation and migration in HER2-positive cell lines, whereas miR-221-3p suppression had the opposite effect. Additionally, miR221-3p mimics reduced the expression levels of LASS2 and MBD2 in HER2-positive breast cancer cells;

    conversely, miR-221-3p inhibition upregulated LASS2 and MBD2. miR-221-3p inhibited the translation of LASS2 and MBD2 by directly binding to their 3′- untranslated regions. Forced expression of LASS2 and MBD2 significantly attenuated the ability of miR-221-3p mimics to enhance cell growth and migration in HER2- positive but not in HER2-negative breast cancer cells. In HER-2-positive breast cancer patients, the levels of miR221-3p were negatively correlated with the mRNA levels of LASS2 and MBD2.

    Conclusions. Upregulation of hsa-miR-221-3 in HER2-positive breast cancer contributes to cancer cell proliferation and migration by directly targeting the tumor suppressors LASS2 and MBD2. Therefore, the hsa-miR-221-3 may serve as a promising and actionable therapeutic target in HER2-positive breast cancer.